DexCom Inc (DXCM) - Total Assets
Based on the latest financial reports, DexCom Inc (DXCM) holds total assets worth $6.63 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DexCom Inc - Total Assets Trend (2000–2025)
This chart illustrates how DexCom Inc's total assets have evolved over time, based on quarterly financial data. Also see market cap of DexCom Inc for the company's overall valuation and market capitalisation.
DexCom Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
DexCom Inc's total assets of $6.63 Billion consist of 63.6% current assets and 36.4% non-current assets. Review DXCM current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.5% |
| Accounts Receivable | $1.29 Billion | 20.4% |
| Inventory | $629.10 Million | 9.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $70.80 Million | 1.1% |
| Goodwill | $24.20 Million | 0.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how DexCom Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See DexCom Inc (DXCM) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DexCom Inc's current assets represent 63.6% of total assets in 2025, a decrease from 96.8% in 2000.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2025, down from 96.8% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 20.4% of total assets.
DexCom Inc Competitors by Total Assets
Key competitors of DexCom Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
COCHLEAR LTD ADR 1/2/O.N.
F:OC50
|
Germany | €2.83 Billion |
|
TransMedics Group Inc
NASDAQ:TMDX
|
USA | $1.46 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.89 Billion |
|
Novocure Ltd
NASDAQ:NVCR
|
USA | $787.93 Million |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.20 Billion |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581
|
China | CN¥2.70 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
DexCom Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 1.50 | 5.78 |
| Quick Ratio | 1.64 | 1.32 | 5.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.11 Billion | $1.52 Billion | $2.87 Billion |
DexCom Inc - Advanced Valuation Insights
This section examines the relationship between DexCom Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.30 |
| Latest Market Cap to Assets Ratio | 4.51 |
| Asset Growth Rate (YoY) | -2.2% |
| Total Assets | $6.34 Billion |
| Market Capitalization | $28.58 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values DexCom Inc's assets at a significant premium (4.51x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: DexCom Inc's assets decreased by 2.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for DexCom Inc (2000–2025)
The table below shows the annual total assets of DexCom Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $6.34 Billion | -2.23% |
| 2024-12-31 | $6.48 Billion | +3.51% |
| 2023-12-31 | $6.26 Billion | +16.19% |
| 2022-12-31 | $5.39 Billion | +9.29% |
| 2021-12-31 | $4.93 Billion | +14.98% |
| 2020-12-31 | $4.29 Billion | +79.14% |
| 2019-12-31 | $2.40 Billion | +25.00% |
| 2018-12-31 | $1.92 Billion | +111.92% |
| 2017-12-31 | $904.10 Million | +124.45% |
| 2016-12-31 | $402.80 Million | +37.95% |
| 2015-12-31 | $292.00 Million | +58.18% |
| 2014-12-31 | $184.60 Million | +50.69% |
| 2013-12-31 | $122.50 Million | +15.57% |
| 2012-12-31 | $106.00 Million | -12.01% |
| 2011-12-31 | $120.47 Million | +56.13% |
| 2010-12-31 | $77.16 Million | +64.36% |
| 2009-12-31 | $46.95 Million | +5.82% |
| 2008-12-31 | $44.37 Million | -42.57% |
| 2007-12-31 | $77.26 Million | +19.68% |
| 2006-12-31 | $64.55 Million | +13.80% |
| 2005-12-31 | $56.73 Million | +93.22% |
| 2004-12-31 | $29.36 Million | +41.37% |
| 2003-12-31 | $20.77 Million | +140.36% |
| 2001-12-31 | $8.64 Million | -39.84% |
| 2000-12-31 | $14.36 Million | -- |
About DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick bloo… Read more